Catalyst

Slingshot members are tracking this event:

Top-line Results from Mallinckrodt's (MNK) Pivotal Phase 3 Clinical Trial of StrataGraft Regenerative Tissue in Patients with Deep Partial-thickness Thermal Burns

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
MNK

100%

Additional Information

Clinical Data Results showed that a significantly smaller area of burn wounds treated with StrataGraft tissue required autografting by three months compared to the area of burn wounds treated exclusively with autograft (p<0.0001). Additionally, results showed that the proportion of StrataGraft-treated wounds that achieved durable wound closure at three months exceeded the pre-defined threshold for statistical significance.
http://mallinckrodt....
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 23, 2019
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Stratagraft, Thermal Burn Injury